Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival

Francesco Spina, Tommaso Radice, Chiara De Philippis, Martina Soldarini, Maria Chiara Di Chio, Anna Dodero, Anna Guidetti, Simonetta Viviani, Paolo Corradini

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18–60 years), 23% had refractory disease (SD/PD). Donors were HLA identical (39%), unrelated (30%), or haploidentical (31%). Median follow-up was 6.2 years. Five-year OS was 59% and PFS was 49%. NRM was 16% at 1 year. 44% of patients had cGVHD, and 14% moderate-to-severe cGVHD at last follow-up. GFRS and cGVHD-free OS were 26 and 48% at 5 years. In multivariate analysis, resistant disease at alloSCT impacted survival and GFRS. In conclusion, disease response before alloSCT impacts survival and GFRS. GVHD outcomes may help comparing the long-term effects of the new salvage treatments that bridge patients to alloSCT.

Original languageEnglish
Pages (from-to)101-109
Number of pages9
JournalLeukemia and Lymphoma
Volume60
Issue number1
DOIs
Publication statusPublished - Jan 2 2019

Fingerprint

Homologous Transplantation
Stem Cell Transplantation
Graft vs Host Disease
Hodgkin Disease
Recurrence
Survival
Disease-Free Survival
Salvage Therapy
Multivariate Analysis
Retrospective Studies
Tissue Donors

Keywords

  • allogeneic transplantation
  • cGVHD-free survival
  • GFRS
  • Hodgkin lymphoma
  • long-term survival

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma : long-term outcomes and graft-versus-host disease-free/relapse-free survival. / Spina, Francesco; Radice, Tommaso; De Philippis, Chiara; Soldarini, Martina; Di Chio, Maria Chiara; Dodero, Anna; Guidetti, Anna; Viviani, Simonetta; Corradini, Paolo.

In: Leukemia and Lymphoma, Vol. 60, No. 1, 02.01.2019, p. 101-109.

Research output: Contribution to journalArticle

@article{b5a8c20056174603b3b7fceb04209ab5,
title = "Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma: long-term outcomes and graft-versus-host disease-free/relapse-free survival",
abstract = "This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18–60 years), 23{\%} had refractory disease (SD/PD). Donors were HLA identical (39{\%}), unrelated (30{\%}), or haploidentical (31{\%}). Median follow-up was 6.2 years. Five-year OS was 59{\%} and PFS was 49{\%}. NRM was 16{\%} at 1 year. 44{\%} of patients had cGVHD, and 14{\%} moderate-to-severe cGVHD at last follow-up. GFRS and cGVHD-free OS were 26 and 48{\%} at 5 years. In multivariate analysis, resistant disease at alloSCT impacted survival and GFRS. In conclusion, disease response before alloSCT impacts survival and GFRS. GVHD outcomes may help comparing the long-term effects of the new salvage treatments that bridge patients to alloSCT.",
keywords = "allogeneic transplantation, cGVHD-free survival, GFRS, Hodgkin lymphoma, long-term survival",
author = "Francesco Spina and Tommaso Radice and {De Philippis}, Chiara and Martina Soldarini and {Di Chio}, {Maria Chiara} and Anna Dodero and Anna Guidetti and Simonetta Viviani and Paolo Corradini",
year = "2019",
month = "1",
day = "2",
doi = "10.1080/10428194.2018.1459607",
language = "English",
volume = "60",
pages = "101--109",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Taylor and Francis Ltd.",
number = "1",

}

TY - JOUR

T1 - Allogeneic transplantation for relapsed and refractory Hodgkin lymphoma

T2 - long-term outcomes and graft-versus-host disease-free/relapse-free survival

AU - Spina, Francesco

AU - Radice, Tommaso

AU - De Philippis, Chiara

AU - Soldarini, Martina

AU - Di Chio, Maria Chiara

AU - Dodero, Anna

AU - Guidetti, Anna

AU - Viviani, Simonetta

AU - Corradini, Paolo

PY - 2019/1/2

Y1 - 2019/1/2

N2 - This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18–60 years), 23% had refractory disease (SD/PD). Donors were HLA identical (39%), unrelated (30%), or haploidentical (31%). Median follow-up was 6.2 years. Five-year OS was 59% and PFS was 49%. NRM was 16% at 1 year. 44% of patients had cGVHD, and 14% moderate-to-severe cGVHD at last follow-up. GFRS and cGVHD-free OS were 26 and 48% at 5 years. In multivariate analysis, resistant disease at alloSCT impacted survival and GFRS. In conclusion, disease response before alloSCT impacts survival and GFRS. GVHD outcomes may help comparing the long-term effects of the new salvage treatments that bridge patients to alloSCT.

AB - This monocentric retrospective study included 70 consecutive relapsed/refractory Hodgkin lymphoma (RR-HL) patients receiving reduced-intensity allogeneic stem cell transplantation (alloSCT). We evaluated overall and progression-free survival (OS, PFS), graft-versus host disease/relapse-free survival (GFRS), and chronic GVHD-free OS (cGVHD-free OS) defined as OS without moderate-to-severe cGVHD. Patients had a median age of 33 years (range, 18–60 years), 23% had refractory disease (SD/PD). Donors were HLA identical (39%), unrelated (30%), or haploidentical (31%). Median follow-up was 6.2 years. Five-year OS was 59% and PFS was 49%. NRM was 16% at 1 year. 44% of patients had cGVHD, and 14% moderate-to-severe cGVHD at last follow-up. GFRS and cGVHD-free OS were 26 and 48% at 5 years. In multivariate analysis, resistant disease at alloSCT impacted survival and GFRS. In conclusion, disease response before alloSCT impacts survival and GFRS. GVHD outcomes may help comparing the long-term effects of the new salvage treatments that bridge patients to alloSCT.

KW - allogeneic transplantation

KW - cGVHD-free survival

KW - GFRS

KW - Hodgkin lymphoma

KW - long-term survival

UR - http://www.scopus.com/inward/record.url?scp=85046484405&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046484405&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1459607

DO - 10.1080/10428194.2018.1459607

M3 - Article

C2 - 29716416

AN - SCOPUS:85046484405

VL - 60

SP - 101

EP - 109

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -